Achieve Life Sciences (ACHV) Other Non Operating Income (2010 - 2026)
Achieve Life Sciences (ACHV) recorded quarterly Other Non Operating Income of -$13000.0 in Q1 2026, down 285.71% on a QoQ basis from $7000.0 in Q4 2025, and down 161.9% year-over-year from $21000.0 in Q1 2025.
Achieve Life Sciences (ACHV) Other Non Operating Income (2010 - 2026) Analysis & Trends
Achieve Life Sciences has disclosed Other Non Operating Income across 17 years of filings, most recently posting -$13000.0 for Q1 2026.
- Quarterly Other Non Operating Income fell 161.9% year-over-year to -$13000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$70000.0 (up 86.59% YoY) and the FY2025 annual result came in at -$36000.0, up 87.28% from the prior year.
- Other Non Operating Income declined to -$13000.0 in Q1 2026, from $7000.0 in the prior quarter.
- Over five years, Other Non Operating Income peaked at $59000.0 in Q4 2022 and troughed at -$283000.0 in Q3 2024.
- A 5-year average of -$33882.4 and a median of -$5000.0 in 2025 frame the typical range for Other Non Operating Income.
- Biggest YoY gain for Other Non Operating Income was 251.28% in 2022; the steepest drop was 2900.0% in 2022.
- Tracing ACHV's Other Non Operating Income over 5 years: stood at $59000.0 in 2022, then sank by 71.19% to $17000.0 in 2023, then slumped by 1617.65% to -$258000.0 in 2024, then jumped by 102.71% to $7000.0 in 2025, then tumbled by 285.71% to -$13000.0 in 2026.
- Business Quant data shows ACHV's Other Non Operating Income at -$13000.0 in Q1 2026, $7000.0 in Q4 2025, and -$5000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Achieve Life Sciences | 93.71 Mn | 63.22 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13,000.00 |
| Dec 31, 2025 | 7,000.00 |
| Sep 30, 2025 | -5,000.00 |
| Jun 30, 2025 | -59,000.00 |
| Mar 31, 2025 | 21,000.00 |
| Dec 31, 2024 | -258,000.00 |
| Sep 30, 2024 | -283,000.00 |
| Jun 30, 2024 | -2,000.00 |
| Mar 31, 2024 | -15,000.00 |
| Dec 31, 2023 | 17,000.00 |
| Sep 30, 2023 | -17,000.00 |
| Jun 30, 2023 | -6,000.00 |
| Mar 31, 2023 | -3,000.00 |
| Dec 31, 2022 | 59,000.00 |
| Sep 30, 2022 | -30,000.00 |
| Jun 30, 2022 | 5,000.00 |
| Mar 31, 2022 | 6,000.00 |
| Dec 31, 2021 | -39,000.00 |
| Sep 30, 2021 | -1,000.00 |
| Jun 30, 2021 | -12,000.00 |